FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

How to steer a useful conversation with a protein: Interferon beta as novel therapy target for age-related macular degeneration (AMD)

A collaboration of FOR 2240 project 6 „Microglia in AMD“ (Principal Investigator Prof.  Thomas Langmann) and the Bayer-University of Cologne Graduate Program of Pharmacology and Experimental Therapeutics (PhD student Anika Lückoff), together with neuro-immunology experts from Freiburg (Prof. Marco Prinz) and Hannover (Prof. Ulrich Kalinke), identified a novel role of interferon beta (IFN-beta) signaling in age-related macular degeneration (AMD).  IFN-beta is a protein, part of the molecular cocktail of substances that “tell” cells what to do when under attack from a virus, etc. Sometimes, these communications do not go well for the organism. The paper appeared in the high-ranking journal EMBO Molecular Medicine that is dedicated to publishing excellent research work that bridges the gaps between basic science and translational medicine. Here, the authors show for the first time that defective interferon signaling in microglia and macrophages (green cells in the image above) can cause choroidal neovascularization (red structures in the image above), a sight-threatening condition of late-stage AMD. Although the immunomodulatory potential of IFN-beta has been studied in an experimental model of AMD, these findings underscore its strategic promise for future therapeutic approaches to controlling chronic inflammation in AMD.

Related posts

DOG Rokohl

DOG Rokohl

March 22, 2022

FOR 2240 Scientist Dr. Alexander C. Rokohl was awarded the Brewitt Publication Prize


Read more
RWA Schlereth 2022

Augenklinik RWA Schlereth 2022

February 18, 2022

Dr. Simona Schlereth wins RWA Science Award 2022


Read more
Yongwei Guo DOG

Yongwei Guo DOG

January 24, 2022

Dr. Yongwei Guo wins DOG Doctoral Award for outstanding dissertation


Read more

News

  • FOR 2240 scientists receive several honors at ARVO 2022
  • FOR 2240 Scientist Dr. Alexander C. Rokohl was awarded the Brewitt Publication Prize
  • Dr. Simona Schlereth wins RWA Science Award 2022
  • Dr. Yongwei Guo wins DOG Doctoral Award for outstanding dissertation
  • FOR 2240 scientist Dr. Alexander Rokohl wins DOG Science Prize “Dry Eye and Blepharitis/MGD”

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck